Nuvalent, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NUVL Nasdaq 2830 www.nuvalent.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nuvalent, Inc.

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones - Jan 12th, 2026 4:30 am
3 Biotech Stocks With Major 2026 Catalysts - Dec 29th, 2025 7:13 am
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Dec 23rd, 2025 10:12 pm
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 22nd, 2025 4:30 am
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - Dec 16th, 2025 5:15 am
Nuvalent Appoints Ron Squarer to Board of Directors - Dec 10th, 2025 2:01 pm
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects - Dec 8th, 2025 10:20 pm
Does Nuvalent’s Recent Trial Success Justify the Stock’s 36% 2025 Rally? - Nov 26th, 2025 11:11 pm
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - Nov 26th, 2025 4:30 am
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - Nov 24th, 2025 2:01 pm
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - Nov 19th, 2025 2:19 pm
Biotech Stock Gets Booted in Latest Fund Update - Nov 19th, 2025 9:56 am
Nuvalent Announces Pricing of Public Offering of Common Stock - Nov 18th, 2025 9:50 pm
Nuvalent aiming for approval on pivotal trial data for NSCLC candidate - Nov 18th, 2025 4:24 am
Nuvalent Tops A Profit-Taking Zone On Its 'Unprecedented' Test Results In Lung Cancer - Nov 17th, 2025 2:40 pm
Nuvalent Announces Public Offering of Common Stock - Nov 17th, 2025 2:01 pm
Nuvalent Says Neladalkib Offers Clinical Benefit in Phase 1/2 ALK-Positive Lung Cancer Trial - Nov 17th, 2025 7:07 am
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC - Nov 17th, 2025 4:30 am
Nuvalent (NUVL): A Closer Look at Valuation as New ALK Inhibitor Data Presentation Approaches - Nov 15th, 2025 4:06 pm
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib - Nov 14th, 2025 2:01 pm